We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Levrett | LSE:LVRT | London | Ordinary Share | GB00BYW79Y38 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMNFX
Nuformix PLC
11 March 2021
REACH: non-regulatory announcement
Nuformix plc
("Nuformix", the "Company" or the "Group")
Initiation of research by Allenby Capital
Cambridge, UK - 11 March 2021: Nuformix plc (LSE:NFX), a pharmaceutical development company and drug re-purposing specialist, is pleased to announce the initiation of research by Allenby Capital Limited, the Company's broker.
The research is available on the Allenby Capital website here:
Allenby Capital
Enquiries:
Nuformix plc Dr Anne Brindley, CEO Fleur Wood, Investor Relations +44 (0)1223 627222 Allenby Capital Limited Tim Sohal / Matt Butlin (Sales and Corporate Broking) Nick Athanas / George Payne (Corporate Finance) +44 (0)203 328 5656
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities.
For more information, please visit www.nuformix.com .
About Reach announcements
This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted companies to distribute media only / non-regulatory news releases into the public domain.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRAFFFFIVFIILIL
(END) Dow Jones Newswires
March 11, 2021 02:00 ET (07:00 GMT)
1 Year Levrett Chart |
1 Month Levrett Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions